Kelly Jason P sold $57K of INSP

Kelly Jason P (See Remarks) sold 963 shares of Inspire Medical Systems, Inc. (INSP) at $59.55 on 2026-08-07.

Original reporting
SEC EDGAR · Kelly Jason P
Published Aug 11, 2026, 11:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INSP
Neutral
medium confidence
Mentioned
$INSP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSPNeutralLow
01

Why it matters

The disclosed open-market sale can be used as a sentiment datapoint, but it does not introduce new operational or financial information about INSP.

02

Market read

Traders may note insider selling, but without accompanying fundamental news, the event is unlikely to drive a major repricing.

03

What to watch

The article does not state motivations, total compensation context, or whether other insiders sold/bought around the same time, limiting inference from one transaction.

Relevance 3/10Novelty 3/10Timing: Form 4 filed 2026-08-11, covering a sale dated 2026-08-07.

Background

The article is a SEC Form 4 insider transaction disclosure for Inspire Medical Systems, Inc.

Company-level read

Ticker impact

$INSPNeutralMedium confidence
Context

Inspire Medical Systems insider Kelly Jason P sold 963 shares at $59.55 on 2026-08-07, per a Form 4 filed 2026-08-11.

Expected impact

Low likelihood of a sustained price move solely from this sale; any impact is likely limited to short-term sentiment.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings, but provides no new company fundamentals, guidance, or legal/regulatory developments.

Market effects

Minimal, as this is a single-insider transaction without sector-wide signals.

None indicated.

None indicated.

Counterpoint

Insider sales are often planned for diversification or liquidity needs; the absence of a stated 10b5-1 plan does not necessarily imply negative information.

Key entities

  • Inspire Medical Systems, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Kelly Jason P

    Officer who sold 963 shares at $59.55 on 2026-08-07.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INSPMedAI 8/10

Inspire (INSP) Q3 2026 Earnings Call Transcript

Inspire (INSP) reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3% sequentially. The company expects stable coding framework in 2027 and a new code in 2028, with strong adoption of Inspire V. Operating loss was $28.7M, and adjusted EPS was $0.14. The company is investing in patient flow optimization and expanding market reach. According to the company, they remain confident in their path to growth.

$INSPMed

Inspire: Q3 Earnings Snapshot

Inspire Medical Systems (INSP) reported a Q3 loss of $24.4M, or 84 cents per share, but adjusted earnings of 14 cents per share, beating estimates. Revenue was $206.7M, also topping forecasts. The company expects full-year earnings of $1.20-$1.40 per share and revenue of $850M-$860M.

$INSPMed

Inspire Medical Systems Q3 Earnings Call Highlights

Inspire Medical Systems (INSP) reported Q3 earnings, estimating coding and reimbursement challenges reduced results by $30M and may impact 2026 results by $120M. The company expects revenue growth in Q4 and low-single-digit growth in 2027, citing stable coding and investments. Inspire highlighted a new CPT code for its Inspire V device and ongoing development of Inspire VI. Management discussed clinical evidence supporting their therapy and plans to invest in patient access and education.

$INSPHighAI 8/10

Inspire Medical Q3 2026 slides: reimbursement clarity ahead, growth reset

Inspire Medical Systems reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3.0% sequentially. The company cited reimbursement challenges as the primary headwind. Shares rose 1.83% in after-hours trading. Inspire highlighted its market position and long-term growth potential, despite near-term slowdowns. The company expects full-year 2026 revenue of $850M-$860M, down from 2025 levels.